Alzamend Neuro announces 1-for-9 reverse stock split effective May 12 to maintain Nasdaq listing

Alzamend Neuro, Inc.

Shares outstanding reduce from ~7,208,591 to ~800,954 at 1-for-9 ratio.
Split effective May 12, 2025; trading symbol remains ALZN with new CUSIP 02262M605.
Reverse split aimed at complying with Nasdaq $1.00 minimum bid price requirement.
No fractional shares issued; holders of fractional shares will receive cash payment.
Par value unchanged at $0.0001 per share; all options/warrants proportionally adjusted.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Certificate of Incorporation amendment effectuating a one-for-nine reverse stock split (effective 2025-05-12).

Change: charter amendment
Effective: 2025-05-12

Exact text from the filing

On May 6, 2025, Alzamend Neuro, Inc. (the “ Company ”), filed an amendment to the Company’s Certificate of Incorporation (the “ Amendment ”) with the State of Delaware to effectuate a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value (“ Common Stock ”) by a ratio of one-for-nine (the “ Reverse Stock Split ”). The Reverse Stock Split will become effective in the State of Delaware at 12:01 AM ET on Monday, May 12, 2025.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-007204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.